title: Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
abstract: BACKGROUND
  Her-2/neu gene overexpression has been found in several malignancies, and is associated with poor prognosis; while its role in the tumorigenesis and progression of prostate cancer (PCa) is still controversial. This study aimed to evaluate the prognostic value of Her-2/neu protein expression and clinicopathologic factors in antiandrogen-treated Chinese men with PCa for disease progression and PCa-specific death.
  
  
  METHODS
  Her-2/neu protein expression was determined using immunohistochemistry (IHC) in specimens collected from 124 prostate biopsies and transurethral resection of prostate (TURP) from seven prostate cancer patients.
  
  
  RESULTS
  Her-2/neu protein expression was 0, 1+, 2+, and 3+ in 40 (30.5%), 8 (6.1%), 67 (51.1%), and 16 (12.2%) cases, respectively. Her-2/neu protein expression showed significant correlation as judged by Gleason score (P = 0.049), clinical tumor-node-metastases (cTNM) stage (P = 0.018) and disease progression (P = 0.001), but did not correlate with prostate-specific antigen (PSA) (P = 0.126) or PCa-specific death (P = 0.585). PSA (P = 0.001), Gleason score (P = 0.017), cTNM (P = 0.000) and Her-2/neu protein expression (P = 0.001) had prognostic value for evaluating the progression of PCa in univariate analysis. In Kaplan-Meier plots, both Gleason score (P = 0.035) and cTNM (P = 0.013) correlated with PCa-specific death. In multivariate analysis, only cTNM was significant for both disease progression (P = 0.001) and PCa-specific death (P = 0.031).
  
  
  CONCLUSIONS
  Her-2/neu protein expression is significantly correlated with Gleason score, cTNM and disease progression, although it is not an independent predictor of disease progression and PCa-specific death. cTNM staging serves as an independent prognostic factor for disease progression and PCa-specific death.
authors.affiliation: Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210008, China.
authors.forename: Yi-Fen
authors.initials: YF
authors.lastname: Zhang
authors.forename: Yang-Bo
authors.initials: YB
authors.lastname: Guan
authors.forename: Bin
authors.initials: B
authors.lastname: Yang
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Wu
authors.forename: Yu-Tian
authors.initials: YT
authors.lastname: Dai
authors.forename: Shuang-Jie
authors.initials: SJ
authors.lastname: Zhang
authors.forename: Ji-Ping
authors.initials: JP
authors.lastname: Wang
authors.forename: Shailendra
authors.initials: S
authors.lastname: Anoopkumar-Dukie
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Davey
authors.forename: Ze-Yu
authors.initials: ZY
authors.lastname: Sun
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases